Intentar ORO - Gratis
Sigachi isn't just a supplier; we are a strategic partner
Express Pharma
|December 2024
Amit Raj Sinha, MD and CEO, Sigachi explains that his company's strategic growth and diversification across excipients, APIs, food, nutrition, and personal care are driven by innovation, sustainability, and a customer-first approach. The company's focus on quality, regulatory compliance, and digital transformation positions it as a trusted global partner across industries
-

What differentiates Sigachi from competitors?
Sigachi stands as an industry leader with an unmatched production scale - 33000 MTPA for its excipients and nutritional premix range, allowing us to fulfill complex client demands with consistent quality and reliability. Our expertise spans multiple verticals, including APIs, excipients, food and nutritional ingredients, and personal care Ingredients, ensuring clients have access to an integrated, one-stop source for high-quality ingredients.
Our commitment to growth aligns with that of our customers growing needs and is reinforced by certain strategic projects, including the upcoming greenfield facility in Dahej SEZ. The state-of-the-art facility will expand our production capacity, support innovation, and set new standards for operational excellence within the industry.
Sigachi's customer-centric approach, combined with a strong emphasis on sustainable operations - from eco-friendly sourcing to waste reduction positions us as a responsible and sustainable, trusted partner. Additionally, our dedication to innovation is supported by continuous R&D investment, poised to grow from a lower single-digit to a mid-single-digit percentage of revenue. Our R&D facility, recognised and approved by Department of Scientific and Industrial Research, Government of India, leads advancements in excipient development and multifunctional ingredient solutions, providing clients with cutting-edge, high-quality products.
Sigachi isn't just a supplier; we are a strategic partner, dedicated to delivering excellence, fostering sustainable growth, and supporting clients across diverse sectors with reliability and agility.
Sigachi has expanded significantly from MCC excipients to APIs, food, nutrition, and personal care. What prompted this diversification, and how do you ensure cohesive growth across such varied sectors?
Esta historia es de la edición December 2024 de Express Pharma.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE Express Pharma

Express Pharma
Flexotherm Heating Tapes & Cords
Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling
1 mins
October 2025

Express Pharma
DRIVING INDIA'S INNOVATION EDGE
Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma Inc's shift from generics to innovation and global leadership
16 mins
October 2025

Express Pharma
Al compass: Transforming pharma commercialisation
As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging Al across nearly every aspect of commercialisation, from market forecasting and personalised marketing to dynamic pricing and beyond. In this article, Neha Aathavale takes the pulse of the industry to explore who is taking note and how companies are beginning to put Al into action in their commercial operations
7 mins
October 2025

Express Pharma
PRIME NEO: New age doors from Gandhi Automation
Gandhi Automations presents the multi-composites, high-performance door PRIME NEO for clean environments. Complete Washable, Greater Sealing and Pressure Resistant.
1 mins
October 2025

Express Pharma
Unani Medicine: At crossroads of tradition and modernity
Manufacturers, academic institutions and research councils are working together to elevate Unani medicine through clinical validation and policy alignment with international standards, finds Swati Rana
7 mins
October 2025

Express Pharma
Single-Use Technologies in Biologics Manufacturing: Benefits, Challenges, and Growing Demand
The biopharmaceutical industry is increasingly adopting single-use technology (SUT) to achieve flexibility, cost efficiency, and faster time-to-market. Compared with stainless steel systems, SUT reduces capital investment, eliminates cleaning and sterilization steps, lowers contamination risk, and shortens production timelines.
1 min
October 2025

Express Pharma
Sustainable packaging with Romaco and Liveo Research
Recycable blister packs
3 mins
October 2025

Express Pharma
With India soon to be three times the population of the EU, it makes perfect sense to have manufacturing here
As part of Sweden's Focus Asia programme, a high-level SME delegation recently visited India to strengthen bilateral ties and explore collaborations across sectors including pharma, biotech and others. Building on the momentum of the \"Time for Sweden\" event, the visit underscored Sweden's commitment to innovation, sustainability, and co-creation with India. Among the delegation was Emil Alexander Byström, CEO of SpinChem AB, who in an interaction with Kalyani Sharma shared his insights on how advanced Swedish technologies like biocatalysis and the company's patented Rotating Bed Reactor (RBR) can accelerate India's pharma and biotech innovation journey while supporting sustainable growth.
3 mins
October 2025

Express Pharma
Cell therapy's next chapter: Industry embraces in-vivo innovation
Nikhil C Bhanumathi, Principal Clinical Lead, Thermo Fisher Scientific highlights that cell therapy is entering a bold new phase in 2025 as the industry shifts from complex, lab-based ex vivo CAR-T to faster, more accessible in vivo CAR-T innovations. This approach promises to expand access, lower costs, and potentially tackle solid tumors and autoimmune diseases
4 mins
October 2025

Express Pharma
Research misconduct ...can delay meaningful and reliable discoveries
Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions
6 mins
October 2025
Listen
Translate
Change font size